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Background
Hepatitis B virus reactivation (HBV-R) is becoming an
increasingly concerning issue as monoclonal antibody
therapy has become widely used for chronic lymphoproli-
ferations. HBV-R can also occur in HBsAg negative
patients who have only HBcAb positive (occult HBV
infection).
We present a non-consecutive HBV-R case series report.
Our series consisted of both HBsAg positive patients and
patients with occult HBV infection, who received mono-
clonal antibody therapy. We present the most important
demographic, clinical and immune-virological features of
HBV-R in these patients.
Case report
We also include the case of a 62 year old male patient with a
previously HBs Ag negative, HBcAb positive status who was
diagnosed with small B cell non Hodgkin lymphoma (NHL).
The liver function tests were normal. The patient started
cyclophosphamide-adriamycin-vincristine-prednisone+
rituximab cycles and preemptive therapy with lamivudine
100 mg/day for HBV-R. After 5 cycles the patient developed
asthenia and anorexia. He had increased serum aminotrans-
ferase (x10 ULN) levels and low platelet count. He tested
negative for HAV, HCV, EBV, CMV markers and positive
for HBV (positive HBsAg, HBcAb and HBeAb), with HBV-
DNA of 79 UI/mL. The patient had HDV total antibodies
and high viral load: HDV-RNA = 555,000,000 geq/mL. He
was diagnosed with hepatitis HDV/HBV reactivation due to
chemotherapy for B cell-NHL. Although NHL was in partial
remission, the chemotherapy and lamivudine were stopped.
He started pegIFN alpha-2a therapy when ALT values were
almost within normal range.
Conclusion
The problem of HBV/HDV hepatitis reactivation in
patients receiving immunosuppressive treatment is insuffi-
ciently known. Preemptive antiviral therapy prior to
monoclonal antibody administration may be crucial for
preventing HBV-R even in the presence of occult HBV
infection. It is important to draw attention to the possibi-
lity of HDV reactivation, as an occult delta virus infection
may be present even in persons with occult HBV infection.
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